早期宫颈腺癌雌孕激素受体表达状态的研究  

Expression Status of Estrogen Receptor and Progesterone Receptor in Early Cervical Adenocarcinoma

作　　者：涂云霞[1] 邓颖辉[1] 熊丹 潘玫[1] TU Yunxia;DENG Yinghui;XIONG Dan(Maternal and Child Health Hospital of Jiangxi Province,Nanchang,330006)

机构地区：[1]江西省妇幼保健院,330006 [2]江西省瑞昌市人民医院,332200

出　　处：《实用癌症杂志》2018年第12期2067-2069,共3页The Practical Journal of Cancer

摘　　要：目的探讨宫颈腺癌雌激素受体(ER)、孕激素受体(PR)表达状态及其与临床病理的关系。方法对200例宫颈腺癌手术标本进行病理检查,采用免疫组化技术检测ER、PR。结果宫颈腺癌在不同病理亚型、绝经前后、FIGO分期、术后病理危险因素方面ER、PR同时阴性率均高于同时阳性率,具有统计学差异(P <0. 05)。结论对于早期宫颈腺癌术后的患者,进行ER、PR检测,可以为术后提供激素替代治疗提供依据,但激素替代治疗是否会对宫颈腺癌患者预后产生不利影响仍需进一步随访及研究。Objective To investigate the expression of estrogen receptor(ER)and progesterone receptor(PR)in cervical adenocarcinoma and its relationship clinicopathological features.Methods The pathological specimens of 200 cases of cervical adenocarcinoma were examined by immunohistochemistry,and ER and PR were detected by immunohistochemistry.Results The negative rates of ER and PR in different pathological subtypes,pre-menopausal and post-menopausal stages,FIGO stages and postoperative pathological risk factors of cervical adenocarcinoma were higher than those of simultaneous positive rates,with statistical differences(P<0.05).Conclusion Considered for early cervical cancer patients after the surgery,detection of ER and PR can provide evidence for postoperative hormone replacement therapy,but whether it will have adverse effects on the prognosis of patients with cervical carcinoma still need further study and research.

关 键 词：宫颈腺癌 雌激素受体 孕激素受体 

分 类 号：R73-36[医药卫生—肿瘤]